Organophosphonic acids as drug candidates

Bibliography

• DANTA M, DUSHEIKO G: Adefovir dipivoxil: review of a novel acyclic nucleoside analogue. Int. J. Clin. Pract. (2004) 58:877-886
   PubMed Web of Science ®Google Scholar
• ERION MD, VAN POELJE PD, DANG Q et al.: MB06322 (CS-917): a potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in Type 2 diabetes. Proc. Natl. Acad. Sci. USA (2005) 102:7970-7975.
   PubMed Web of Science ®Google Scholar
• HUNTER T: Signaling – 2000 and beyond. Cell (2000) 100:113-127.
   PubMed Web of Science ®Google Scholar
• ZHANG ZY: Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. Ann. Rev. Pharmacol. Toxicol. (2002) 42:209-234.
   PubMed Web of Science ®Google Scholar
• ELCHEBLY M, PAYETTE P, MICHALISZYN E et al.: Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science (1999) 283:1544-1548.
   PubMed Web of Science ®Google Scholar
• KLAMAN LD, BOSS O, PERONI OD et al.: Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol. Cell Biol. (2000) 20:5479-5489.
   PubMed Web of Science ®Google Scholar
• ZINKER BA, RONDINONE CM, TREVILLYAN JM et al.: PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc. Natl. Acad. Sci. USA (2002) 99:11357-11362.
   PubMed Web of Science ®Google Scholar
• VAN HUIJSDUIJNEN RH, BOMBRUN A, SWINNEN D: Selecting protein tyrosine phosphatases as drug targets. Drug Discov. Today (2002) 7:1013-1019.
   PubMed Web of Science ®Google Scholar
• LIU G: Protein tyrosine phosphatase 1B inhibition: opportunities and challenges. Curr. Med. Chem. (2003) 10:1407-1421.
   PubMed Web of Science ®Google Scholar
• LYON MA, DUCRUET AP, WIPF P, LAZO JS: Dual-specificity phosphatases as targets for antineoplastic agents. Nat. Rev. Drug Discov. (2002) 1:961-976.
   PubMed Web of Science ®Google Scholar
• DUFRESNE C, ROY P, WANG Z et al.: The development of potent non-peptidic PTP1B inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:1039-1042.
   PubMed Web of Science ®Google Scholar
• REED CE, KITA H: The role of protease activation of inflammation in allergic respiratory diseases. J. Allergy Clin. Immunol. (2004) 114:997-1008.
   PubMed Web of Science ®Google Scholar
• SPURZEM JR, RENNARD SI: Pathogenesis of COPD. Semin. Respir. Crit. Care Med. (2005) 26:142-53.
   PubMed Web of Science ®Google Scholar
• DE GARAVILLA L, GRECO MN, SUKUMAR N et al.: A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase. J. Biol. Chem. (2005) 280:18001-18007.
   PubMed Web of Science ®Google Scholar
• KOLTERMAN OG, GRAY RS, GRIFFIN J et al.: Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus. J. Clin. Invest. (1981) 68:957-969.
   PubMed Web of Science ®Google Scholar
• DEFRONZO RA: The triumvirate: β cell, muscle, liver. A collusion responsible for NIDDM. Diabetes (1998) 37:667-687.
   Google Scholar
• CONSOLI A, NURJHAN N, CAPANI F, GERICH J: Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes (1989) 38:550-557.
   PubMed Web of Science ®Google Scholar
• ROTHMAN DL, MAGNUSSON I, KATZ LD, SHULMAN RG, SHULMAN GI: Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science (1991) 254:573-576.
   PubMed Web of Science ®Google Scholar
• MAGNUSSON I, ROTHMAN DL, KATZ LD, SHULMAN RG, SHULMAN GI: Increased rate of gluconeogenesis in Type II diabetes mellitus. A 13C nulear magnetic resonance study. J. Clin. Invest. (1992) 90:1323-1327.
   PubMed Web of Science ®Google Scholar
• WAJNGOT A, CHANDRAMOULI V, SCHUMANN WC et al.: Quantitative contributions of gluconeogenesis to glucose production during fasting in Type 2 diabetes mellitus. Metabolism (2001) 50:47-52.
   PubMed Web of Science ®Google Scholar
• VENEZIALE CM, DONOFRIO JC, HANSEN JB, JOHNSON ML, MAZZOTTA MY: Intracellular concentration and specific activity of carbohydrate-metabolizing enzymes. Application of specific radioimmunoassay. In: The Regulation of Carbohydrate Formation and Utilization in Mammals. Veneziale CM (Ed.), University Park Press, Baltimore, USA (1981):23-44.
   Google Scholar
• PILKIS SJ, GRANNER DK: Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Ann. Rev. Physiol. (1992) 54:885-909.
   PubMed Web of Science ®Google Scholar
• VAN SCHAFTINGEN E, HERS HG: Inhibition of fructose-1,6-bisphosphatase by fructose-2,6-bisphosphate. Proc. Natl. Acad. Sci. USA (1981) 78:2861-2863.
   PubMed Web of Science ®Google Scholar
• PILKIS SJ, EL-MAGHRABI MR, PILKIS J, CLAUS T: Inhibition of fructose-1,6-bisphosphatase by fructose-2,6-bisphosphate. J. Biol. Chem. (1981) 256:3619-3622.
   PubMed Web of Science ®Google Scholar
• PILKIS SJ, EL-MAGHRABI MR, CLAUS TH: Hormonal regulation of hepatic gluconeogenesis and glycolysis. Ann. Rev. Biochem. (1988) 57:755-783.
   PubMed Web of Science ®Google Scholar
• TAKETA K, POGELL BM: Allosteric inhibition of rat liver fructose-1,6-bisphosphatase by adenosine 5′-monophosphate. J. Biol. Chem. (1965) 240:651-662.
   PubMed Web of Science ®Google Scholar
• KE H, LIANG JY, ZHANG Y, LIPSCOMB WN: Conformational transition of fructose-1,6-bisphosphatase: Structure comparison between the AMP complex (T form) and the fructose 6-phosphate complex (R form). Biochemistry (1991) 30:4412-4420.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, LIANG JY, HUANG S, LIPSCOMB WN: Toward a mechanism for the allosteric transition of pig kidney fructose-1,6-bisphosphatase. J. Mol. Biol. (1994) 244:609-624.
   PubMedGoogle Scholar
• WRIGHT SW, CARLO AA, DANLEY DE et al.: 3-(2-Carboxy-ethyl)-4,6-dichloro-1H-indole-2-carboxylic acid: an allosteric inhibitor of fructose-1,6-bisphosphatase bind at the AMP site. Bioorg. Med. Chem. Lett. (2003) 13:2055-2058.
   Google Scholar
• WRIGHT SW, CARLO AA, CARTY MD et al.: Anilinoquinazoline inhibitors of fructose-1,6-bisphosphatase bind at a novel allosteric site: synthesis, in vitro characterization, and X-ray crystallography. J. Med. Chem. (2002) 45:3865-3877.
   PubMed Web of Science ®Google Scholar
• MARYANOFF BE, REITZ AB, TUTWILER GF, BENKOVIC SJ, BENKOVIC PA, PILKIS SJ: Stereoselective synthesis and biological activity of β- and α-D-arabinose 1,5-diphosphate: analogues of a potent metabolic regulator. J. Am. Chem. Soc. (1984) 106:7851-7853.
   Web of Science ®Google Scholar
• OMENN GS, BERESFORD SA, MOTULSKY AG: Preventing coronary heart disease: B vitamins and homocysteine. Circulation (1998) 97:421-424.
   PubMedGoogle Scholar
• ROBINSON K, ARHEART K, REFSUM H et al.: Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. Circulation (1998) 97:437-443.
   PubMed Web of Science ®Google Scholar
• GORDON CP, KELLER PA: Control of hepatitis C: a medicinal chemistry perspective. J. Med. Chem. (2005) 48:1.
   Google Scholar
• WU JZ, HONG Z: Targeting NS5B RNA-dependent RNA polymerase for anti-HCV chemotherapy. Curr. Drug Targets Infect. Disord. (2003) 3:207-219.
   PubMedGoogle Scholar
• KOH Y, SHIM JH, WU JZ, ZHONG W, HONG Z, GIRARDET JL: Design, synthesis, and antiviral activity of adenosine 5′-phosphonate analogues as chain terminators against hepatitis C virus. J. Med. Chem. (2005) 48:2867-2875.
   PubMed Web of Science ®Google Scholar
• FARQUHAR D, SRIVASTVA DN, KATTESCH NJ, SAUNDERS PP: Biologically reversible phosphate-protective groups. J. Pharm. Sci. (1983) 72:324-325.
   PubMedGoogle Scholar
• LEFEBVRE I, PERIGAUD C, POMPON A et al.: Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: Intracellular delivery of 3′-azido-2′,3′-dideoxythymidine 5′-minophosphate. J. Med. Chem. (1995) 38:3941-3950.
   PubMed Web of Science ®Google Scholar
• ERION MD, REDDY KR, BOYER SH et al.: Design, synthesis, and characterization of a series of cytochrome P450 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. J. Am. Chem. Soc. (2004) 126:5154-5163.
   PubMed Web of Science ®Google Scholar
• ERION MD, VAN POELJE PD, MACKENNA DA et al.: Liver-targeted drug delivery using HepDirect prodrugs. J. Pharm. Exp. Ther. (2005) 312:554-560.
   PubMed Web of Science ®Google Scholar
• MCGUIGAN C, PATHIRANA RN, BALZARINI J, DE CLERCQ E: Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT. J. Med. Chem. (1993) 36:1048-1052.
   PubMed Web of Science ®Google Scholar